Medtronic, Inc. Stock Earnings: 3 Key Takeaways

Medtronic beats earnings estimates for the first quarter. Here are the top three takeaways from the earnings report.

Aug 19, 2014 at 10:26AM

Medtronic (NYSE:MDT) just reported its earnings for the first quarter of fiscal 2015, topping analyst estimates on both the top and bottom lines.

Medtronic reported that its revenue rose 5% year over year to $4.27 billion, topping the consensus estimate of $4.25 billion. Non-GAAP diluted earnings per share rose 6% to $0.93, beating estimates by a penny, while GAAP diluted earnings fell 6% to $0.87 per share.

MDT Chart

Source: YCharts

The company reiterated its prior top and bottom line guidance for fiscal 2015, expecting full-year-revenue growth between 3% to 5% on a constant currency basis, and diluted non-GAAP EPS to grow 6% to 9% year over year to a range between $4.00 to $4.10 per share. The company also reaffirmed its commitment to acquiring Covidien, the Dublin-based medical device and pharmaceutical company. 

Let's take a look at three key takeaways from Medtronic's earnings, and what they could mean for investors in the long run.

Slow and steady growth at its Cardiac and Vascular Group
Revenue at Medtronic's Cardiac and Vascular Group, its largest business segment, rose 4% year over year to $2.25 billion.

Within that group, Cardiac Rhythm and Heart Failure device sales rose 5% to $1.26 billion, with high-power devices like the Viva XT CRT-D and low-power devices like the Reveal LINQ insertable cardiac monitor posting strong growth.

Coronary and Structural Heart revenue climbed 2% to $766 million, while Aortic and Peripheral device revenue rose 6% to $232 million, thanks to rising market shares for its Endurant II and Valiant Captivia stent grafts, and strong overseas demand for its IN.PACT Admiral and Pacific drug-coated balloons.

Medtronic's main competitor in cardiac and vascular devices, St. Jude Medical, reported that total cardiac rhythm device sales rose 2% year over year to $733 million last quarter, while sales of cardiovascular (vascular and heart structural) products rose 3% to $351 million.

From this comparison, we can see that Medtronic continues to post in-line growth with its rivals, while steadily forging ahead with newer products. Meanwhile, the closely watched race between Medtronic and St. Jude to make the smallest, leadless pacemakers should keep the company's heart and vascular business "thumping along" nicely. 

Slumping spine sales hurt Restorative Therapies
Medtronic's Restorative Therapies group, which consists of spine, neuromodulation, and surgical technologies, reported 3% revenue growth to $1.6 billion. The group was mainly supported by its neuromodulation and surgical businesses, which were offset by declines in the spine business.

Neuromodulation revenue rose 12% to $479 million, thanks to strong sales of Pain Stim, DBS, and Gastro/Uro devices. The segment has also gained a lot of attention thanks to its Activa "brain pacemaker," which uses deep brain stimulation systems to help treat debilitating neurological disorders. Surgical technologies revenue rose 6% to $381 million, thanks to steady growth at its ENT, Neurosurgery, and Advanced Energy businesses.

But the spine business posted a 3% decline to $743 million, due to soft sales in Core Spine and BMP (bone morphogenetic protein) products. Demand for BMP products has waned since last year, when physicians started using smaller kits on a smaller number of patients.

Medtronic's strength in neuromodulation and surgical businesses, offset by weakness in its spine business, is reflected elsewhere across the industry. Stryker (NYSE: SYK), for example, reported that its neurotechnology revenue rose 8.3% last quarter to $245 million, while surgical devices revenue rose 7.6% to $340 million. But Stryker's spine revenue also fell 1.6% to $185 million.

Investors should note that the spine business, despite its current doldrums, has some nice growth opportunities long term. Research firm Markets and Markets forecasts that the global spine surgical devices market should grow at a compound annual growth rate of 5.1% between 2012 and 2017, rising from $11.6 to $14.8 billion -- indicating that the slowdown will hopefully only be temporary.

Strong growth in diabetes
Medtronic's smallest segment, its Diabetes Group, remains its fastest growing one thanks to strong demand in the U.S. for the MiniMed 530G with Enlite, a first-generation wearable "artificial pancreas," which automatically stops insulin delivery when glucose levels fall below a preset threshold.

Revenue at the group rose 13% year-over-year to $416 million. But investors should note that although the MiniMed 530G doesn't have much competition at the moment, Johnson & Johnson's Animas division and DexCom have a competing device, the Vibe, which could be approved later this year in the U.S. The Vibe is already available in Europe, Australia, and Canada.

If that happens, growth at the diabetes group could stall out, forcing Medtronic to accelerate the launch schedule of second generation devices like the MiniMed 640G, a closed-loop system which will arrive in Europe in April 2015.

The Foolish takeaway
In conclusion, Medtronic delivered another solid quarter, showing steady growth at its core businesses in line with industrywide trends, and exhibiting strong growth in newer ones.

Demand for its cardiovascular products will likely remain robust, and I would expect its spine business to recover along with the rest of the industry. Newer diabetes products should also help it maintain its lead over its rivals, which are still struggling to gain market approval in the U.S. Looking further ahead, the Covidien acquisition could bolster Medtronic's bottom line with a tax inversion, as well as diversify its portfolio with additional medical devices that complement its core businesses.

Leaked: This coming blockbuster will make even Medtronic jealous
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers